Acquisitions and License Agreements (Schedule of Reconciliation of Total Consideration) (Details) (USD $) In Millions, unless otherwise specified	0 Months Ended		0 Months Ended		0 Months Ended
	Aug. 14, 2014 Questcor Pharmaceuticals, Inc.	Aug. 14, 2014 Questcor Pharmaceuticals, Inc.	Mar. 19, 2014 Cadence Pharmaceuticals, Inc.	Oct. 01, 2012 CNS Therapeutics, Inc.	Mar. 19, 2014 Specialty Pharmaceuticals Cadence Pharmaceuticals, Inc.	Oct. 01, 2012 Specialty Pharmaceuticals CNS Therapeutics, Inc.
Business Acquisition [Line Items]
Total consideration, net of cash	$ 5,470.2		$ 1,286.0			$ 95.0
Plus: cash assumed in acquisition		445.1	43.2			3.6
Total consideration	5,915.3		1,329.2		1,300.0	98.6
Less: unpaid purchase consideration		(128.8)
Less: contingent consideration		0	0	(6.9)		(6.9)
Net assets acquired		$ 5,786.5	$ 1,329.2			$ 91.7